Structure of 56621-89-7
*Storage:
*Shipping:
4.5
*For Research Use Only !
Change View
Size | Price | US Stock | Global Stock | In Stock |
250mg | łÇď¶ÊÊ | Inquiry | Inquiry | |
1g | łËÿ¶ÊÊ | Inquiry | Inquiry | |
5g | łÇÊî¶ÊÊ | Inquiry | Inquiry | |
10g | łËÇď¶ÊÊ | Inquiry | Inquiry | |
25g | łÿÍ˶ÊÊ | Inquiry | Inquiry |
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
łÇď¶ÊÊ
łËÿ¶ÊÊ
łÇÊî¶ÊÊ
łËÇď¶ÊÊ
łÿÍ˶ÊÊ
In Stock
- +
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 56621-89-7 |
Formula : | C5H7N3O |
M.W : | 125.13 |
SMILES Code : | C1=C(N)C=NC(=N1)OC |
MDL No. : | MFCD08234878 |
InChI Key : | HKHRENFWPKWVML-UHFFFAOYSA-N |
Pubchem ID : | 352904 |
GHS Pictogram: | ![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Num. heavy atoms | 9 |
Num. arom. heavy atoms | 6 |
Fraction Csp3 | 0.2 |
Num. rotatable bonds | 1 |
Num. H-bond acceptors | 3.0 |
Num. H-bond donors | 1.0 |
Molar Refractivity | 32.93 |
TPSA ? Topological Polar Surface Area: Calculated from | 61.03 Ų |
Log Po/w (iLOGP)? iLOGP: in-house physics-based method implemented from | 1.14 |
Log Po/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by | -0.17 |
Log Po/w (WLOGP)? WLOGP: Atomistic method implemented from | 0.08 |
Log Po/w (MLOGP)? MLOGP: Topological method implemented from | -0.9 |
Log Po/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by | 0.2 |
Consensus Log Po/w? Consensus Log Po/w: Average of all five predictions | 0.07 |
Log S (ESOL):? ESOL: Topological method implemented from | -0.94 |
Solubility | 14.5 mg/ml ; 0.116 mol/l |
Class? Solubility class: Log S scale | Very soluble |
Log S (Ali)? Ali: Topological method implemented from | -0.66 |
Solubility | 27.6 mg/ml ; 0.221 mol/l |
Class? Solubility class: Log S scale | Very soluble |
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by | -1.38 |
Solubility | 5.24 mg/ml ; 0.0419 mol/l |
Class? Solubility class: Log S scale | Soluble |
GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg | High |
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg | No |
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) | No |
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) | No |
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) | No |
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) | No |
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) | No |
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) | No |
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from | -7.18 cm/s |
Lipinski? Lipinski (Pfizer) filter: implemented from | 0.0 |
Ghose? Ghose filter: implemented from | None |
Veber? Veber (GSK) filter: implemented from | 0.0 |
Egan? Egan (Pharmacia) filter: implemented from | 0.0 |
Muegge? Muegge (Bayer) filter: implemented from | 1.0 |
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat | 0.55 |
PAINS? Pan Assay Interference Structures: implemented from | 0.0 alert |
Brenk? Structural Alert: implemented from | 0.0 alert: heavy_metal |
Leadlikeness? Leadlikeness: implemented from | No; 1 violation:MW<1.0 |
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) | 1.89 |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With copper; In methanol; at 150℃; for 24h;Sealed tube; | General procedure: To a solution of 5-chloropyrazin-2-amine (0.2 g, 1.54 mmol) in MeOH (3 mL) was added Cu powder (0.13 g, 2.07 mmol), followed by a solution of sodium methoxide in MeOH (0.38 mL, 1.75 mmol). The reaction mixture was stirred at 150C in a sealed tube for 24 h. The reaction mixture was then filtered through Celite, and the filtrate was concentrated in vacuo. The crude product obtained was purified by column chromatography (silica: 100-200 mesh, MeOH:DCM 2-3%) to afford the title compound (0.13 g, 67%). LCMS (ES+) 126 (M+H)+, RT 1.06 minutes (method 1). | |
With copper; In methanol; at 150℃; for 24h;Sealed tube; | General procedure: Intermediate 22 5-Methoxypyrazin-2-amine [0242] To a solution of 5-chloropyrazin-2-amine (0.2 g, 1.54 mmol) in MeOH (3 mL) was added Cu powder (0.13 g, 2.07 mmol), followed by a solution of sodium methoxide in MeOH (0.38 mL, 1.75 mmol). The reaction mixture was stirred at 150 C. in a sealed tube for 24 h. The reaction mixture was then filtered through Celite, and the filtrate was concentrated in vacuo. The crude product obtained was purified by column chromatography (silica: 100-200 mesh, MeOH: DCM 2-3%) to afford the title compound (0.13 g, 67%). LCMS (ES+) 126 (M+H)+, RT 1.06 minutes (method 1). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
100% | With hydrogen;palladium 10% on activated carbon; In methanol; at 20℃; under 635.0 Torr; for 18h; | Example 40Synthesis of 4-[2-(difluoromethyl)-4-methoxy-1H-benzimidazol-1-yl]-N-(2-methoxy-5-pyrimidinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-amineThe compound was synthesized according to Method A.To a solution of sodium methoxide (0.090 g of sodium) in MeOH (12 mL) was added 0.486 g (3.03 mmol) of 2-chloro-5-nitropyrimidine, and the mixture was heated under reflux for 1 hr. After cooling, the mixture was concentrated in vacuo, extracted with EtOAc, and washed with water. The aqueous layer was extracted with CHCl3 and the combined organic layers were dried (Na2SO4), and concentrated, to give 0.347 g (75% yield) of 2-methoxy-5-nitropyrimidine as a yellow powder: 1H NMR (CDCl3) delta9.31 (s, 2H), 4.17 (s, 3H); LCMS (APCI+) m/z: 156 (MH+, 100%).To 0.342 g (2.20 mmol) of the above nitro compound in MeOH (20 mL) was added 0.30 g of 10% Pd/C and the mixture was stirred under hydrogen (25 in/Hg) for 18 hrs. The reaction mixture was filtered through celite, and concentrated, to give 0.274 g (100% yield) of 5-amino-2-methoxypyrimidine as a colorless oil: 1H NMR (DMSO-d6) delta 8.05 (s, 2H), 3.94 (s, 3H); LCMS (APCI+) m/z: 126 (MH+, 100%).To 0.274 g (2.19 mmol) of the above amino compound in THF (3 mL) was added 1.25 mL of NaHMDS (2 M solution in THF) and the mixture was stirred for 10 min. A solution of 0.31 g (0.78 mmol) of 1-[4-chloro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-2-(difluoromethyl)-4-methoxy-1H-benzimidazole in THF (5 mL) was added and the resulting mixture was stirred for 90 min. The reaction mixture was neutralized with acetic acid, diluted with water, and extracted with EtOAc. The organic layer was washed with water and aq. NH3, dried, and concentrated. Recrystallization from EtOH/CH2Cl2 gave 0.098 g (26% yield) of 4-[2-(difluoromethyl)-4-methoxy-1H-benzimidazol-1-yl]-N-(2-methoxy-5-pyrimidinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-amine: mp 255-258 C.; 1H NMR (DMSO-d6) 810.07 (s, 1H), 8.88-8.74 (m, 2H), 8.15-7.42 (m, 3H), 6.97 (d, J=8.0 Hz, 1H), 3.98 (s, 3H), 3.93 (s, 3H), 3.82-3.72 (m, 8H); Anal. Calcd. for C21H21F2N6O3: C, 52.0; H, 4.4; N, 26.0. Found: C, 52.1; H, 4.5; N, 26.0%. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
81% | General procedure: To a mixture of <strong>[56621-89-7]2-methoxypyrimidine-5-amine</strong> (120 mg) and pyridine (4 ml) was added phenyl chlorocarbonate (0.132 ml) under ice bath cooling, followed by stirring at room temperature for 1.5 hours. Thereafter, a mixture of 2-chloro-4-[(2S,5R)-2,5-dimethylpiperazin-1-yl]benzonitrile (200 mg) and pyridine (3 ml) was added thereto, followed by stirring at 100 C. for 1 hour. After cooling, the reaction solution was concentrated under reduced pressure, and toluene (15 ml×2) was added to the residue and the azeotrope was evaporated. Ethyl acetate (20 ml) was added to the residue, followed by washing with a saturated aqueous sodium hydrogen carbonate solution and saturated brine and dried over anhydrous sodium sulfate. Then the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol=100/0 to 96/4), to afford 258 mg (81%) of (2R,5S)-4-(3-chloro-4-cyanophenyl)-N-(2-methoxypyrimidin-5-yl)-2,5-dimethylpiperazine-1-carboxamide |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
25% | Example 82 Preparation of 2-[1-(4-fluorophenyl)-3-[2-(4-methoxyphenyl)ethyl]-5-oxo-2-sulfanylideneimidazolidin-4-yl]-N-(2-methoxypyrimidin-5-yl)acetamide. TBTU (244 mg; 0.74 mmol; 1.5 eq) and DIPEA (170 muL; 0.99 mmol; 2 eq) were added to a solution of 2-[1-(4-fluorophenyl)-3-[2-(4-methoxyphenyl)ethyl]-5-oxo-2-sulfanylideneimidazolidin-4-yl]acetic acid (1-21) (200 mg; 0.50 mmol; 1 eq) in anhydrous dioxane (8 mL). The reaction mixture was stirred at room temperature for 30 minutes. 2-Methoxypyrimidin-5-amine (124 mg; 0.99 mmol; 2 eq) was added and the reaction mixture was stirred at room temperature for 18 hours. Saturated ammonium chloride (20 mL) was added and the aqueous layer was extracted with ethyl acetate (2 x 30 mL). The combined organic layers were washed with saturated sodium chloride (1 x 20 mL), filtered and evaporated to dryness. The crude was purified on silica gel using dichloromethane/methanol (98/2) as an eluent. After trituration in diethyl ether, the title compound 2-[1-(4-fluorophenyl)-3-[2-(4-methoxyphenyl)ethyl]-5-oxo-2-sulfanylidene imidazolidin-4-yl]-N-(2-methoxypyrimidin-5-yl)acetamide was obtained in 25 % yield (79 mg) as a white solid. 1H-NMR (Acetone-d6): delta (ppm) delta 2.96 (m, 1H), 3.09 (m, 1H), 3.24 (m, 1H), 3.43 (m, 1H), 3.75 (s, 3H), 3.78 (m, 1H), 3.92 (s, 3H), 4.30 (m, 1H), 4.65 (s, 1H), 6.86 (m, 2H), 7.25 (m, 4H), 7.45 (m, 2H), 8.75 (m, 2H) 9.62 (m, 1H); MS (ESI+): m/z = 509.9 [M+H]+. | |
25% | Example 82: Preparation of2-[l-(4-fluorophenyl)-3-[2-(4-methoxyphenyl)ethyl]-5- oxo-2-mlfanylideneimid zolidin-4-yl]-N-{2-methoxypyrim TBTU (244 mg; 0.74 mmol; 1.5 eq) and DIPEA (170 mu 0.99 mmol; 2 eq) were added to a solution of 2-[l-(4-fluorophenyl)-3-[2-(4-methoxyphenyl)ethyl]-5-oxo-2- sulfanylideneimidazolidin-4-yl]acetic acid (1-21) (200 mg; 0.50 mmol; 1 eq) in anhydrous dioxane (8 mL). The reaction mixture was stirred at room temperature for 30 minutes. 2-Methoxypyrimidin-5-amine (124 mg; 0.99 mmol; 2 eq) was added and the reaction mixture was stirred at room temperature for 18 hours. Saturated ammonium chloride (20 mL) was added and the aqueous layer was extracted with ethyl acetate (2 x 30 mL). The combined organic layers were washed with saturated sodium chloride (1 x 20 mL), filtered and evaporated to dryness. The crude was purified on silica gel using dichloromethane/methanol (98/2) as an eluent. After trituration in diethyl ether, the title compound 2-[l-(4-fluorophenyl)-3-[2-(4- methoxyphenyl)ethyl]-5-oxo-2-sulfanylideneimidazolidin-4-yl]-N-(2- methoxypyrimidin-5-yl)acetamide was obtained in 25% yield (79 mg) as a white solid. 1H-NMR (Acetone-d6): delta (ppm) delta 2.96 (m, 1H), 3.09 (m, 1H), 3.24 (m, 1H), 3.43 (m, 1H), 3.75 (s, 3H), 3.78 (m, 1H), 3.92 (s, 3H), 4.30 (m, 1H), 4.65 (s, 1H), 6.86 (m, 2H), 7.25 (m, 4H), 7.45 (m, 2H), 8.75 (m, 2H) 9.62 (m, 1H); MS (ESI+): m/z = 509.9 [M+H]+ . |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
28% | Example 79 Preparation of 2-(3-{2-[4-(dimethylamino)phenyl]ethyl}-1-(4-fluorophenyl)-5-oxo-2-sulfanylideneimidazolidin-4-yl)-N-(2-methoxypyrimidin-5-yl)acetamide. TBTU (177.2 mg; 0.54 mmol; 1.5 eq) and DIPEA (126 muL; 0.72 mmol; 2 eq) were added to a solution of 2-(3- {2-[4-(dimethylamino)phenyl]ethyl}-1-(4-fluorophenyl)-5-oxo-2-sulfanylideneimidazolidin-4-yl)acetic acid (1-37) (150 mg; 0.36 mmol; 1 eq) in dioxane (6 mL). The reaction mixture was stirred at room temperature for 30 minutes. A solution of <strong>[56621-89-7]2-methoxypyrimidin-5-amine</strong> (90.3 mg; 0.72 mmol; 2 eq) in dimethylformamide (2 mL) was added and the reaction mixture was stirred at room temperature overnight. The mixture was concentrated to dryness. Saturated ammonium chloride was added (15 mL) and the aqueous layer was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with saturated sodium chloride (3 x 20 mL), dried over sodium sulfate and concentrated to dryness. The crude was purified by flash chromatography on silica gel using cyclohexane/ethyl acetate (25/75 to 0/100) as an eluent. After trituration in diethyl ether/dichloromethane, the title compound 2-(3-{2-[4-(dimethylamino)phenyl]ethyl}-1-(4-fluorophenyl)-5-oxo-2-sulfanylidene imidazolidin-4-yl)-N-(2-methoxypyrimidin-5-yl)acetamide was obtained in 28 % yield (52 mg) as an off-white solid. 1H-NMR (DMSO-d6): delta (ppm) 2.75 (m, 1H), 2.84 (s, 6H), 2.94 (m, 1H), 3.15 (d, 1H), 3.28 (m, 1H), 3.64 (m, 1H), 3.89 (s, 3H), 4.13 (m, 1H), 4.73 (m, 1H), 6.65 (d, 2H), 7.07 (d, 2H), 7.37 (m, 4H), 8.72 (d, 2H), 10.5 (s, 1H); MS (ESI+): m/z = 522.9 [M+H]+. | |
28% | Example 79: Preparation of 2-(3-{2-[4-(dimethylamino)phenyl]ethyl}-l-(4- fluorophenyl)-5-oxo-2-sulfanylideneimidazolidin-4-yl)-N-(2-methoxypyrim yl)acetamide. TBTU (177.2 mg; 0.54 mmol; 1.5 eq) and DIPEA (126 mu 0.72 mmol; 2 eq) were added to a solution of 2-(3-{2-[4-(dimethylamino)phenyl]ethyl}-l-(4-fluorophenyl)- 5-oxo-2-sulfanylideneimidazolidin-4-yl)acetic acid (1-37) (150 mg; 0.36 mmol; 1 eq) in dioxane (6 mL). The reaction mixture was stirred at room temperature for 30 minutes. A solution of <strong>[56621-89-7]2-methoxypyrimidin-5-amine</strong> (90.3 mg; 0.72 mmol; 2 eq) in dimethylformamide (2 mL) was added and the reaction mixture was stirred at room temperature overnight. The mixture was concentrated to dryness. Saturated ammonium chloride was added (15 mL) and the aqueous layer was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with saturated sodium chloride (3 x 20 mL), dried over sodium sulfate and concentrated to dryness. The crude was purified by flash chromatography on silica gel using cyclohexane/ethyl acetate (25/75 to 0/100) as an eluent. After trituration in diethyl ether/dichloromethane, the title compound 2-(3-{2-[4-(dimethylamino) phenyl]ethyl}-l-(4-fluorophenyl)-5-oxo-2-sulfanylideneimidazolidin-4-yl)-N-(2- methoxypyrimidin-5-yl)acetamide was obtained in 28% yield (52 mg) as an off- white solid. 1H-NMR (DMSO-d6): delta (ppm) 2.75 (m, IH), 2.84 (s, 6H), 2.94 (m, IH), 3.15 (d, IH), 3.28 (m, IH), 3.64 (m, IH), 3.89 (s, 3H), 4.13 (m, IH), 4.73 (m, IH), 6.65 (d, 2H), 7.07 (d, 2H), 7.37 (m, 4H), 8.72 (d, 2H), 10.5 (s, IH); MS (ESI+): m/z = 522.9 [M+H]+ . |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
55% | With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine; In 1,4-dioxane; N,N-dimethyl-formamide; at 20℃; | Example 80 Preparation of 2-[1-(4-fluorophenyl)-2,5-dioxo-3-[2-(thiophen-2-yl)ethyl]imidazolidin-4-yl]-N-(2-methoxypyrimidin-5-yl)acetamide. TBTU (265.8 mg; 0.83 mmol; 1.5 eq), followed by DIPEA (288 muL; 1.66 mmol; 3 eq) and after 10 minutes, <strong>[56621-89-7]2-methoxypyrimidin-5-amine</strong> (103.6 mg; 0.83 mmol; 1.5 eq) were added to a solution of 2-[1-(4-fluorophenyl)-2,5-dioxo-3-[2-(thiophen-2-yl)ethyl] imidazolidin-4-yl] acetic acid (1-17) (200 mg; 0.55 mmol; 1 eq) in dioxane/dimethylformamide (3 mL/300 muL). The reaction mixture was stirred at room temperature overnight. Saturated sodium hydrogenocarbonate (15 mL) was added and the aqueous layer was extracted with ethyl acetate (3 x 15 mL). The combined organic layers were washed with saturated sodium chloride (3 x 5 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude was purified by flash chromatography on silica gel using dichloromethane/methanol (100/0 to 97/3) as an eluent. After washing in hydrochloric acid 1M and trituration in diethyl ether, the title compound, 2-[1-(4-fluorophenyl)-2,5-dioxo-3-[2-(thiophen-2-yl)ethyl] imidazolidin-4-yl]-N-(2-methoxypyrimidin-5-yl)acetamide, was obtained in 55% yield (143 mg) as beige solid. 1H-NMR (CDCl3): delta (ppm) 2.83 (m, 1H), 2.96 (m, 1H), 3.25 (m, 2H), 3.5 (m, 1H), 4.01 (m, 4H), 4.31 (m, 1H), 6.92 (m, 2H), 7.16 (m, 3H), 7.39 (m, 2H), 7.61 (s, 1H), 8.66 (m, 2H); MS (ESI+): m/z = 469.9 [M+H]+. |
55% | With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine; In 1,4-dioxane; N,N-dimethyl-formamide; at 20℃; | Example 80: Preparation of 2-[l-(4-fluorophenyl)-2,5-dioxo-3-[2-(thiophen-2- l)ethyl]imidazolidin-4-yl]-N-(2-methoxypyrimidin-5-yl)acetamide. TBTU (265.8 mg; 0.83 mmol; 1.5 eq), followed by DIPEA (288 mu 1-66 mmol; 3 eq) and after 10 minutes, <strong>[56621-89-7]2-methoxypyrimidin-5-amine</strong> (103.6 mg; 0.83 mmol; 1.5 eq) were added to a solution of 2-[l-(4-fluorophenyl)-2,5-dioxo-3-[2-(thiophen-2- yl)ethyl]imidazolidin-4-yl] acetic acid (1-17) (200 mg; 0.55 mmol; 1 eq) in dioxane/dimethylformamide (3 mL/300 mu). The reaction mixture was stirred at room temperature overnight. Saturated sodium hydrogenocarbonate (15 mL) was added and the aqueous layer was extracted with ethyl acetate (3 x 15 mL). The combined organic layers were washed with saturated sodium chloride (3 x 5 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude was purified by flash chromatography on silica gel using dichloromethane/methanol (100/0 to 97/3) as an eluent. After washing in hydrochloric acid 1M and trituration in diethyl ether, the title compound, 2-[l-(4- fluorophenyl)-2,5-dioxo-3-[2-(thiophen-2-yl)ethyl]irnidazolidin-4-yl]-N-(2- methoxypyrimidin-5-yl)acetamide, was obtained in 55% yield (143 mg) as beige solid. 1H-NMR (CDC13): delta (ppm) 2.83 (m, 1H), 2.96 (m, 1H), 3.25 (m, 2H), 3.5 (m, 1H), 4.01 (m, 4H) , 4.31 (m, 1H) , 6.92 (m, 2H), 7.16 (m, 3H) , 7.39 (m, 2H), 7.61 (s, 1H) , 8.66 (m, 2H); MS (ESI+): m/z = 469.9 [M+H]+ . |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
28% | With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine; In 1,4-dioxane; N,N-dimethyl-formamide; at 20℃; | Example 81 Preparation of 2-[1-(4-fluorophenyl)-5-oxo-2-sulfanylidene-3-[2-(thiophen-2-yl)ethyl]imidazolidin-4-yl]-N-(2-methoxypyrimidin-5-yl)acetamide. TBTU (254.5 mg; 0.79 mmol; 1.5 eq), followed by DIPEA (276 muL; 1.59 mmol; 3 eq) and after 10 minutes, <strong>[56621-89-7]2-methoxypyrimidin-5-amine</strong> (99.12 mg; 0.79 mmol; 1.5 eq) were added to a solution of 2-[1-(4-fluorophenyl)-5-oxo-2-sulfanylidene-3-[2-(thiophen-2-yl) ethyl]imidazolidin-4-yl]acetic acid (I-19) (200 mg; 0.53 mmol; 1 eq) in dioxane/dimethylformamide (3 mL/300 muL). The reaction mixture was stirred at room temperature overnight. Saturated sodium hydrogenocarbonate (15 mL) was added and the aqueous layer was extracted with ethyl acetate (3 x 15 mL). The combined organic layers were washed with saturated sodium chloride (3 x 5 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude was purified by flash chromatography on silica gel using dichloromethane/methanol (100/0 to 98/2) as an eluent. After washing with 1M hydrochloric acid and trituration in diethyl ether, the title compound, 2-[1-(4-fluorophenyl)-5-oxo-2-sulfanylidene-3-[2-(thiophen-2-yl) ethyl]imidazolidin-4-yl]-N-(2-methoxypyrimidin-5-yl)acetamide, was obtained in 28 % yield (71 mg) as beige solid. 1H-NMR (DMSO-d6): delta (ppm) 3.2 (m, 4H), 3.75 (m, 1H), 3.88 (s, 3H), 4.26 (m, 1H), 4.75 (m, 1H), 6.97 (m, 2H), 7.37 (m, 5H), 8.71 (m, 2H), 10.47 (s, 1H); MS (ESI+): m/z = 485.8 [M+H]+. |
28% | With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine; In 1,4-dioxane; N,N-dimethyl-formamide; at 20℃; | Example 81: Preparation of 2-[l-(4-fluorophenyl)-5-oxo-2-sulfanylidene-3-[2- (thiophen-2-yl)ethyl]imidazolidin-4-yl]-N-(2-methoxypyrim TBTU (254.5 mg; 0.79 mmol; 1.5 eq), followed by DIPEA (276 mu 1-59 mmol; 3 eq) and after 10 minutes, <strong>[56621-89-7]2-methoxypyrimidin-5-amine</strong> (99.12 mg; 0.79 mmol; 1.5 eq) were added to a solution of 2-[l-(4-fluorophenyl)-5-oxo-2-sulfanylidene-3-[2- (thiophen-2-yl)ethyl]imidazolidin-4-yl]acetic acid (1-19) (200 mg; 0.53 mmol; 1 eq) in dioxane/dimethylformamide (3 mL/300 mu). The reaction mixture was stirred at room temperature overnight. Saturated sodium hydrogenocarbonate (15 mL) was added and the aqueous layer was extracted with ethyl acetate (3 x 15 mL). The combined organic layers were washed with saturated sodium chloride (3 x 5 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude was purified by flash chromatography on silica gel using dichloromethane/methanol (100/0 to 98/2) as an eluent. After washing with 1M hydrochloric acid and trituration in diethyl ether, the title compound, 2-[l-(4- fluorophenyl)-5-oxo-2-sulfanylidene-3-[2-(thiophen-2-yl)ethyl]imidazolidin-4-yl]-N- (2-methoxypyrimidin-5-yl)acetamide, was obtained in 28% yield (71 mg) as beige solid. 1H-NMR (DMSO-d6): delta (ppm) 3.2 (m, 4H), 3.75 (m, 1H), 3.88 (s, 3H) , 4.26 (m, 1H), 4.75 (m, 1H), 6.97 (m, 2H) , 7.37 (m, 5H) , 8.71 (m, 2H) , 10.47 (s, 1H); MS (ESI+): m/z = 485.8 [M+H]+ . |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
33% | c) 2-(3-{2-[4-(Dimethylamino)phenyl]ethyl}-1-(4-fluorophenyl)-2,5-dioxoimidazolidin-4-yl)-N-(2-methoxypyrimidin-5-yl)acetamide (example 78). [0255] TBTU (187.1 mg; 0.57 mmol; 1.5 eq) and DIPEA (131 muL; 0.75 mmol; 2 eq) were added to a solution of 2-(3-{2-[4-(dimethylamino)phenyl]ethyl}-1-(4-fluorophenyl)-5-oxo-2-sulfanylideneimidazolidin-4-yl)acetic acid (1-39) (150 mg; 0.38 mmol; 1 eq) in dioxane (6 mL). The reaction mixture was stirred at room temperature for 30 minutes. Then, <strong>[56621-89-7]2-methoxypyrimidin-5-amine</strong> (93.8 mg; 0.75 mmol; 2 eq) in dimethylformamide (2 mL) was added and the reaction mixture was stirred at room temperature overnight. The mixture was concentrated to dryness. Saturated ammonium chloride was added (15 mL) and the aqueous layer was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with saturated sodium chloride (3 x 20 mL), dried over sodium sulfate and concentrated to dryness. The crude was purified by flash chromatography on silica gel using cyclohexane/ ethyl acetate (25/75 to 0/100) as an eluent. After trituration in diethyl ether/ dichloromethane/pentane, the title compound 2-(3-{2-[4-(dimethylamino)phenyl]ethyl}-1-(4-fluorophenyl)-2,5-dioxoimidazolidin-4-yl)-N-(2-methoxypyrimidin-5-yl)acetamide was obtained in 33% yield (63.8 mg) as an off-white solid. 1H-NMR (DMSO-d6): delta (ppm) 2.69 (m, 1H), 2.80 (m, 1H), 2.83 (s, 6H), 3.02 (d, 1H), 3.12 (d, 1H), 3.28 (m, 1H), 3.68 (m, 1H), 3.88 (s, 3H), 4.51 (m, 1H), 6.64 (d, 2H), 7.05 (d, 2H), 7.36 (m, 4H), 8.71 (s, 2H), 10.39 (s, 1H); MS (ESI+): m/z = 506.9 [M+H]+. | |
33% | c) 2-(3-|2-r4-(Dimethylamino)phenyllethyl)- l-(4-fluorophenyl)-2,5- dioxoimidazolidin-4-yl)-N-(2-methoxypyrimidin-5-yl)acetamide (example 78). TBTU (187.1 mg; 0.57 mmol; 1.5 eq) and DIPEA (131 mu 0.75 mmol; 2 eq) were added to a solution of 2-(3-{2-[4-(dimethylamino)phenyl]ethyl}-l-(4-fluorophenyl)- 5-oxo-2-sulfanylideneimidazolidin-4-yl)acetic acid (T39) (150 mg; 0.38 mmol; 1 eq) in dioxane (6 mL). The reaction mixture was stirred at room temperature for 30 minutes. Then, <strong>[56621-89-7]2-methoxypyrimidin-5-amine</strong> (93.8 mg; 0.75 mmol; 2 eq) in dimethylformamide (2 mL) was added and the reaction mixture was stirred at room temperature overnight. The mixture was concentrated to dryness. Saturated ammonium chloride was added (15 mL) and the aqueous layer was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with saturated sodium chloride (3 x 20 mL), dried over sodium sulfate and concentrated to dryness. The crude was purified by flash chromatography on silica gel using cyclohexane/ethyl acetate (25/75 to 0/100) as an eluent. After trituration in diethyl ether/dichloromethane/pentane, the title compound 2-(3-{2-[4- (dimethylamino)phenyl]ethyl}-l-(4-fluorophenyl)-2,5-dioxoimidazolidin-4-yl)-N-(2- methoxypyrimidin-5-yl)acetamide was obtained in 33% yield (63.8 mg) as an off- white solid. 1H-NMR (DMSO-d6): delta (ppm) 2.69 (m, 1H), 2.80 (m, 1H), 2.83 (s, 6H), 3.02 (d, 1H), 3.12 (d, 1H), 3.28 (m, 1H), 3.68 (m, 1H), 3.88 (s, 3H), 4.51 (m, 1H), 6.64 (d, 2H), 7.05 (d, 2H), 7.36 (m, 4H), 8.71 (s, 2H), 10.39 (s, 1H); MS (ESI+): m/z = 506.9 [M+H]+ . |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
In 1,4-dioxane; at 100℃; | 2-[(2-Chloro-6-fluorobenzyl)amino]-N-(2-methoxypyrimidin-5- yl)benzenesulfonamide (lntB2) The title compound (106 mg, impure, used without further purification) was prepared in two steps from 2-fluorobenzenesulfonyl chloride (0.46 mL, 3.5 mmol) and 5-amino- 2-methoxypyrimidine (482 mg, 3.85 mmol) in 1 ,4-dioxane at 100C; followed by 2- chloro-6-fluorobenzyl amine (0.36 mL, 2.8 mmol) in MeCN (1.5 mL) at 180C in a Biotage Initiator microwave reactor using the methods of (IntBI). LCMS (Method A): m/z 421.2, 423.2 (M-H)- (ES-), at 0.13 and 1.13 min, 95% TLC: Rf = 0.64 (iso-hexane:EtOAc) |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
60% | With tris-(dibenzylideneacetone)dipalladium(0); caesium carbonate; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene; In 1,4-dioxane; at 150℃; for 0.333333h;Microwave irradiation; | A mixture of 2-bromo-N-ieri-butyl-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[2,3- b]pyrazine-7-carboxamide (150 mg, 351 muiotaetaomicron), <strong>[56621-89-7]2-methoxypyrimidin-5-amine</strong> (65.9 mg, 526 muiotaetaomicron), xantphos (60.9 mg, 105 muiotaetaomicron), Pd2(dba)3 (32.1 mg, 35.1 muiotaetaomicron) and cesium carbonate (229 mg, 702 muiotaetaomicron) in dioxane (2 mL) was heated in a microwave at 150C for 20 min. The mixture was cooled then filtered through a pad of celite. The filtrate was concentrated in vacuo then purified by chromatography (silica, 40-80 % ethyl acetate in hexanes) to give N-ieri-butyl- 2-(2-methoxypyrimidin-5-ylamino)-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[2,3- b]pyrazine-7-carboxamide (99 mg, 210 muiotaetaomicron, 60 %) as a yellow solid. (EI/CI) m/z: 484.3 [M + H]. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
73% | To a homogeneous mixture of (+-)-methyl 3-(5-amino-4-(diisobutylamino)-2-fluorophenyl)pentanoate (compound 1128D, 25.4 mg, 0.07 mmol) in THF (1 mL), at room temperature in a sealable vial, was added 4-nitrophenyl carbonochloridate (25 mg, 0.12 mmol). The resulting mixture was stirred at ambient temperature for one hour before 4-ethoxy-2-fluoroaniline, HCl (41 mg, 0.22 mmol) and TEA (0.10 mL, 0.72 mmol) were added. The mixture was then stirred at 50 C. for 16 hours then at room temperature for two hours before MeOH (0.5 mL) was added to the reaction vial followed by LiOH (aq) (1M solution, 0.5 mL, 0.50 mmol). After 1.5 hours, the reaction was treated with LiOH (aq) (1M solution, 0.5 mL, 0.50 mmol) and stirred for 20 hours before being treated with acetic acid (0.06 mL, 1.05 mmol). The mixture was diluted with DMSO then purified by preparative RP HPLC (MeCN/H2O gradient+10-mM NH4OAc) to afford Example 1137 (22.6 mg, 60% yield); 12385] Example 1140 (25.7 mg, 73% yield) was preparedfollowing a procedure analogous to that for the synthesis ofExample 1137, except that <strong>[56621-89-7]2-methoxypyrimidin-5-amine</strong>(27.1 mg, 0.22 mmol) was used instead of 4-ethoxy-2-fluoroaniline, HC1. ?H NMR (500 MHz, DMSO-d5) oe 9.55(s, 1H), 8.66 (s, 2H), 7.85 (s, 1H), 7.80 (d, J=8.1 Hz, 1H),7.03 (d, J=11.9 Hz, 1H), 3.88 (s, 3H), 3.20-3.08 (m, 1H),2.75-2.61 (m, 4H), 2.58-2.54 (m, 2H), 1.71-1.59 (m, 3H),1.54-1.41 (m, 1H), 0.89-0.80 (m, 12H), 0.72 (t, J=7.3 Hz,3H). MS(ES): mlz=490 [M+H]. Tr=1.82 mm (Method C). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
2.12 g | With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine; In dichloromethane; for 2h;Reflux; | A solution of 3-(t-butoxy)-3-oxopropionic acid (CAS No. 40052-13-9) (1.41 g, 8.79 mmol, 1.1 equivalents), <strong>[56621-89-7]2-methoxypyrimidin-5-amine</strong> (CAS No. 56621-89-7) (1.00 g, 7.99 mmol, 1.0 equivalents), triethylamine (1.34 mL, 9.59 mmol, 1.2 equivalents) and EDC (1.84 g, 9.59 mmol, 1.2 equivalents) in DCM (20 mL) was heated to reflux for 2 hours. The reaction mixture was cooled down to room temperature. To the reaction mixture was added a saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with DCM. The organic layer was concentrated under reduced pressure. The residue was purified with silica gel column chromatography (silica gel, 50%-100% ethyl acetate/n-heptane) to afford the title compound (2.12 g). 1H-NMR (400 MHz, CDCl3) delta (ppm): 1.52 (s, 9H), 3.42 (s, 2H), 4.01 (s, 3H), 8.76 (s, 2H), 9.52 (br. s, 1H). |
Tags: 56621-89-7 synthesis path| 56621-89-7 SDS| 56621-89-7 COA| 56621-89-7 purity| 56621-89-7 application| 56621-89-7 NMR| 56621-89-7 COA| 56621-89-7 structure
A238631 [908099-97-8]
2-Methoxy-4-methylpyrimidin-5-amine
Similarity: 0.83
A203765 [14048-15-8]
2,4-Dimethoxypyrimidin-5-amine
Similarity: 0.78
A238631 [908099-97-8]
2-Methoxy-4-methylpyrimidin-5-amine
Similarity: 0.83
A203765 [14048-15-8]
2,4-Dimethoxypyrimidin-5-amine
Similarity: 0.78
A284294 [944901-04-6]
(2-Methoxypyrimidin-4-yl)methanamine
Similarity: 0.76
A238631 [908099-97-8]
2-Methoxy-4-methylpyrimidin-5-amine
Similarity: 0.83
A203765 [14048-15-8]
2,4-Dimethoxypyrimidin-5-amine
Similarity: 0.78
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL